Compounds > lonidamine
Page last updated: 2024-08-23

lonidamine and paclitaxel

lonidamine has been researched along with paclitaxel in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (22.22)18.2507
2000's3 (33.33)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Berruti, A; Dogliotti, L; Gorzegno, G; Tampellini, M1
Bearzatto, A; De Marco, C; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N1
Caporusso, L; Catino, A; Crucitta, E; De Lena, M; Fanizza, G; Gargano, G; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D1
Amadori, D; De Paola, F; Frassineti, GL; Milandri, C; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W1
Amiji, M; Duan, Z; Milane, L2
Amiji, M; Duan, ZF; Milane, L1
Assanhou, AG; Kong, L; Li, W; Mo, R; Sun, H; Xue, L; Zhang, C; Zhang, L1

Trials

1 trial(s) available for lonidamine and paclitaxel

ArticleYear
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2001

Other Studies

8 other study(ies) available for lonidamine and paclitaxel

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide.
    Chest, 1997, Volume: 111, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Indazoles; Middle Aged; Paclitaxel; Remission Induction; Salvage Therapy; Thymoma; Thymus Neoplasms; Vincristine

1997
Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
    International journal of cancer, 1998, Oct-29, Volume: 78, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mitotic Index; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Protamine Kinase; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1998
Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Drug Interactions; Humans; Indazoles; Liver Neoplasms; Paclitaxel; Tumor Cells, Cultured

2003
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
    Molecular pharmaceutics, 2011, Feb-07, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Resistance, Multiple; ErbB Receptors; Female; Humans; Indazoles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Polymers

2011
Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
    Nanomedicine : nanotechnology, biology, and medicine, 2011, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Female; Indazoles; Mice; Mice, Nude; Nanoparticles; Nanotechnology; Paclitaxel

2011
Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; Paclitaxel; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2011
Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
    Biomaterials, 2015, Volume: 73

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hyaluronic Acid; Indazoles; Lipids; Liposomes; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Paclitaxel; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Vitamin E

2015